Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 186 of 6351
-
Can a new pill outsmart Drug-Resistant leukemia?
Disease control Not yet recruitingBackground: Chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) are diseases in which the body makes too many white blood cells that do not work properly. Because white cells play a role in immune function, people with CLL/SLL may be at greater risk of infections…
Phase 2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Sep 10, 2026 03:00 UTC
-
Can a vaccine plus a Blood-Vessel blocker stop airway growths from coming back?
Disease control Not yet recruitingBackground: Recurrent respiratory papillomatosis (RRP) is a rare disease that causes wart-like growths called papillomas to grow in the airway, most often in the voice box, windpipe, or lungs. These growths can make it hard to speak or breathe. Surgery can remove the papillomas,…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 03:00 UTC
-
PET scans may predict which breast cancer patients benefit from elacestrant
Disease control Not yet recruitingThe goal of this clinical trial is to evaluate whether elacestrant, an oral selective oestrogen receptor degrader, can improve outcomes in patients with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer…
Phase 2 • Sponsor: Jules Bordet Institute • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Smart glasses aim to stop nearsightedness before it starts
Prevention Not yet recruitingPre-myopia refers to a condition in which children have not yet developed myopia but exhibit insufficient hyperopic reserve (≤ +0.75 D). This is particularly relevant for young children aged 6 years and under; if their hyperopic reserve is depleted prematurely and they progress i…
Sponsor: Shanghai Eye Disease Prevention and Treatment Center • Aim: Prevention
Last updated Aug 20, 2026 00:00 UTC
-
New immunotherapy targets rare cancers by harnessing the Body's immune system
Disease control Not yet recruitingThis phase II trial studies how well brenetafusp (IMC-F106C) works in treating patients with preferentially expressed antigen of melanoma (PRAME) positive synovial sarcoma and myxoid/round cell liposarcoma that has spread from where it first started (primary site) to other places…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can engineered cells beat blood cancers that Won't quit?
Disease control Not yet recruitingThis is an investigator-initiated, single-center, dose-escalation and dose-expansion early-phase clinical study to evaluate the safety and efficacy of iMagic Injection in participants with hematologic malignancies. The study consists of two cohorts: Cohort 1 enrolls participants …
Early phase 1 • Sponsor: Suzhou Immunofoco Biotechnology Co., Ltd • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Shocking the saphenous nerve: a new way to calm an overactive bladder?
Disease control Not yet recruitingThe goal of this clinical trial is to study the NiNA System and how it works to treat overactive bladder. Up to 290 participants will be enrolled in the study in the USA and Australia. The investigational NiNA System includes a wearable neurostimulator device ("NiNA" or "Device"…
Phase 3 • Sponsor: NinaMED Pty Ltd • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Double-Targeted therapy aims to outsmart Hard-to-Treat lung cancer
Disease control Not yet recruitingTo explore the efficacy and safety of first-line EGFR-TKI combined with Trastuzumab Rezetecan in advanced NSCLC patients harboring EGFR mutations with concomitant HER2 genomic alterations or HER2 protein expression (1+/2+/3+)
Phase 2 • Sponsor: Yongsheng Wang • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a new injection shrink advanced solid tumors?
Disease control Not yet recruitingThis is a multi-center, open-label, phase 1/2 study to evaluate the safety, efficacy, and pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of HY07121 for Injection (Subcutaneous) in participants with advanced solid tumors.
Phase 1/2 • Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a TB vaccine be upgraded to fight RSV in seniors?
Vaccine Not yet recruitingThis Phase 2 clinical study will evaluate the safety of the rBCG-N-RSV vaccine compared to conventional BCG in adults older than 60 years. It will also compare the cellular anti-mycobacterial immune response of both vaccines in adults older than 60 years and characterize the cell…
Phase 2 • Sponsor: Biothervax SpA • Aim: Vaccine
Last updated Aug 15, 2026 00:00 UTC
-
AI uncovers hidden target: could a powerful drug shrink 'HER2-Null' breast tumors?
Disease control Not yet recruitingThis is a prospective, multicenter, single-arm study designed to verify the efficacy and safety of trastuzumab deruxtecan (T-DXd) in subjects with hormone receptor-positive (HR+) unresectable and/or metastatic breast cancer who are identified as HER2-ultralow by artificial intell…
Sponsor: Shuangyue Liu • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a stroke drug shrink brain damage after clot removal?
Disease control Recruiting nowThis phase 2, multicenter, randomized, double-blind, placebo-controlled trial will evaluate the efficacy and safety of anisodine hydrobromide in patients with acute ischemic stroke undergoing endovascular thrombectomy.
Phase 2 • Sponsor: Capital Medical University • Aim: Disease control
Last updated Sep 10, 2026 03:00 UTC
-
Can an extra drug stop amoebic liver abscess from coming back?
Disease control Not yet recruitingLiver abscess is a common cause of presentation to medical emergency. Among the various causes of liver abscess, Amoebic liver abscess (ALA) is a frequent cause that can resemble pyogenic infections in tropical regions. Prompt diagnosis and empirical antimicrobials along with dra…
Phase 3 • Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a new drug combo shrink metastatic colorectal tumors?
Disease control Not yet recruitingThis study is an open-label, multi-center Phase Ib/II clinical trial evaluating the safety and efficacy of LBL-024 in combination with other drugs for the treatment of metastatic colorectal carcinoma (mCRC), aiming to evaluate the safety and efficacy of LBL-024 in combination wit…
Phase 1/2 • Sponsor: Nanjing Leads Biolabs Co.,Ltd • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New hope for SMA babies: boosting gene therapy with a Follow-Up drug
Disease control Recruiting nowIn this study, researchers will learn more about the safety and effects of BIIB115, also known as salanersen. Specifically, researchers will learn more about how salanersen works in babies who have already been treated with onasemnogene abeparvovec (OA) after being diagnosed with…
Phase 3 • Sponsor: Biogen • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug combo aims to stall endometrial cancer
Disease control Not yet recruitingThe purpose of this study is to see how well mocertatug rezetecan (Mo-Rez) in combination with physician's choice of immunotherapy (dostarlimab or pembrolizumab) works as maintenance therapy in participants with advanced or recurrent endometrial cancer (EC) compared with the phys…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a new pill shrink advanced solid tumors?
Disease control Recruiting nowA Phase 1/2, Open-Label, First-in-Human Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumour Activity of ODM-216 in Participants With Advanced Solid Tumours
Phase 1/2 • Sponsor: Orion Corporation, Orion Pharma • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a single drug calm lupus kidney disease without a cocktail of meds?
Disease control Not yet recruitingLupus nephritis (LN) is a frequent and severe complication of systemic lupus erythematosus, with important mortality and morbidity. International 2024 guidelines recommend immunosuppressive therapy (MMF, cyclophosphamide, calcineurin inhibitors, rituximab, azathioprine) in patien…
Phase 2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a herbal formula match traditional medicine for brain bleeds?
Disease control Not yet recruitingThis is a multicenter, randomized, double-blind, controlled, non-inferiority clinical trial to evaluate the efficacy and safety of Huayu Jiedu Formula (FTFY-919) Chinese medicine formula granules compared with traditional decoction in patients with acute hypertensive intracerebra…
Phase 3 • Sponsor: Guangzhou University of Traditional Chinese Medicine • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a Low-Dose ketamine infusion outsmart delirium in heart failure?
Disease control Not yet recruitingDelirium is an acute, fluctuating disturbance in attention and cognition that commonly complicates the course of critically ill patients, particularly those admitted with acute heart failure (AHF). Its occurrence in the intensive care unit (ICU) is associated with prolonged mecha…
Phase 4 • Sponsor: Alexandria University • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC